Leading biopharmaceutical companies report mixed financial results amid strategic pipeline reshuffles and market pressures. Adaptive Biotechnologies posts a 36% revenue increase driven by minimal residual disease test adoption, while Qiagen raises its full-year guidance following 7% growth in Q2 revenues. BridgeBio shows growth in ATTR drug sales, with shares reacting to investor expectations. Meanwhile, BioNTech cuts 90 jobs to refine its pipeline focus, and Terns Pharmaceuticals plans to cease metabolic disease trial funding, seeking partnerships. These dynamics reflect industry adaptation to competitive, regulatory, and economic environments.